Credit Suisse Group began coverage on shares of Galera Therapeutics (NASDAQ:GRTX) in a research note released on Monday morning, Benzinga reports. The brokerage issued a neutral rating and a $14.00 price objective on the stock.
Several other research firms have also recently commented on GRTX. Bank of America began coverage on Galera Therapeutics in a report on Monday. They issued a buy rating and a $15.00 price target for the company. Citigroup began coverage on Galera Therapeutics in a report on Monday. They issued a buy rating and a $20.00 price target for the company.
GRTX opened at $12.07 on Monday. Galera Therapeutics has a 12 month low of $11.50 and a 12 month high of $14.88.
Galera Therapeutics Company Profile
Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.
Read More: What is a short straddle?
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.